What Amgen (AMGN)'s Expanded UPLIZNA Approval in Generalized Myasthenia Gravis Means For Shareholders

Simply Wall St.12-16 13:12

Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, adding a third U....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591988627?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/24816-main-header/1756203123218","is_english":true,"pubTime":"2025-12-16 13:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591988627","market":"hk","top_or_hot":-1,"title":"What Amgen (AMGN)'s Expanded UPLIZNA Approval in Generalized Myasthenia Gravis Means For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, adding a third U....</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/what-amgen-amgns-expanded-uplizna-approval-in-generalized-my\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Amgen (AMGN)'s Expanded UPLIZNA Approval in Generalized Myasthenia Gravis Means For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Amgen (AMGN)'s Expanded UPLIZNA Approval in Generalized Myasthenia Gravis Means For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-16 13:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/what-amgen-amgns-expanded-uplizna-approval-in-generalized-my><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, adding a third U....</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/what-amgen-amgns-expanded-uplizna-approval-in-generalized-my\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/what-amgen-amgns-expanded-uplizna-approval-in-generalized-my","article_id":"2591988627","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/24816-main-header/1756203123218"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/what-amgen-amgns-expanded-uplizna-approval-in-generalized-my","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591988627","pubTimestamp":1765861973,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, adding a third U.S. indication to the therapy’s label.\nThe twice-yearly CD19-targeted B-cell therapy offers a differentiated option in a rare, autoimmune neuromuscular disease area where treatment choices have been relatively limited, reinforcing Amgen’s presence in specialized immunology.\nWe’ll now examine how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4588":"碎股","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4581":"高盛持仓","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4599":"减肥药","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU0122379950.USD":"贝莱德世界健康科学A2","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4566":"资本集团","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","AMGN":"安进","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC"},"translate_title":"安进(AMGN)扩大UPLIZNA治疗全身性重症肌无力的批准对股东意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1.5},"content_text":"Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, adding a third U.S. indication to the therapy’s label. The twice-yearly CD19-targeted B-cell therapy offers a differentiated option in a rare, autoimmune neuromuscular disease area where treatment choices have been relatively limited, reinforcing Amgen’s presence in specialized immunology. We’ll now examine how this expanded UPLIZNA approval, with its low-frequency dosing and rare-disease focus, could reshape Amgen’s investment narrative. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.Amgen Investment Narrative RecapTo own Amgen, you have to believe its broad biologics portfolio, rare-disease focus and disciplined capital return can offset pricing pressure, biosimilar erosion and heavier R&D spending. The expanded UPLIZNA label reinforces the rare-disease and immunology story, but it does not materially change the near term focus on defending key franchises like Prolia and managing rising R&D and manufacturing investment, which remain the central risk to margins and cash generation right now. Among recent announcements, Amgen’s decision to lift its quarterly dividend to US$2.52 per share for Q1 2026 looks most relevant. It highlights management’s confidence in cash flow durability even as the company leans into higher late stage R&D and absorbs biosimilar pressure. For investors, that mix of income support and reinvestment sits alongside new approvals like UPLIZNA as part of the same catalyst: whether Amgen can keep funding growth while preserving financial flexibility. Yet while UPLIZNA broadens Amgen’s rare-disease reach, investors should still be aware of the mounting biosimilar and drug pricing threat that could... Read the full narrative on Amgen (it's free!)Amgen’s narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028.Uncover how Amgen's forecasts yield a $322.88 fair value, in line with its current price.Exploring Other PerspectivesAMGN 1-Year Stock Price Chart The most optimistic analysts already expected Amgen’s revenue to reach about US$42.8 billion and earnings US$13.3 billion, and they see UPLIZNA-style launches as proof that volume driven growth and expanding margins could offset pricing and patent risks far more than consensus assumes.Explore 5 other fair value estimates on Amgen - why the stock might be worth as much as 69% more than the current price!Build Your Own Amgen NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Amgen research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.Searching For A Fresh Perspective?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.Outshine the giants: these 26 early-stage AI stocks could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechNew: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591988627","isCrawlerRequest":true}